Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Baxter International Inc meets primary efficacy endpoint in phase 3 trial of BAX 111, investigational stand-alone recombinant treatment for von willebrand disease


Wednesday, 16 Apr 2014 08:48am EDT 

Baxter International Inc:Announces topline results from a phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111.BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder.The primary endpoint was the number of patients experiencing successful treatment for bleeding episodes. Secondary endpoints included additional efficacy and safety measures, pharmacokinetics and health-related quality of life (HRQoL).